Impact of CCR5Δ32 on the risk of infection, Staphylococcus aureus carriage, and plasma concentrations of chemokines in Danish blood donorsResearch in context
Khoa Manh Dinh,
Kathrine Agergård Kaspersen,
Susan Mikkelsen,
Bertram Dalskov Kjerulff,
Jens Kjærgaard Boldsen,
Mikkel Steen Petersen,
Kristoffer Sølvsten Burgdorf,
Erik Sørensen,
Bitten Aagaard,
Barbara Forman-Ankjær,
Mie Topholm Bruun,
Karina Banasik,
Thomas Folkmann Hansen,
Mette Nyegaard,
Palle Duun Rohde,
Søren Brunak,
Henrik Hjalgrim,
Sisse Rye Ostrowski,
Ole Birger Pedersen,
Henrik Ullum,
Lise Tornvig Erikstrup,
Christian Erikstrup
Affiliations
Khoa Manh Dinh
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Corresponding author. Department of Clinical Immunology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 65, 8200 Aarhus N, Denmark.
Kathrine Agergård Kaspersen
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Danish Big Data Centre for Environment and Health (BERTHA), Aarhus University, Aarhus, Denmark
Susan Mikkelsen
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Bertram Dalskov Kjerulff
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Danish Big Data Centre for Environment and Health (BERTHA), Aarhus University, Aarhus, Denmark
Jens Kjærgaard Boldsen
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Danish Big Data Centre for Environment and Health (BERTHA), Aarhus University, Aarhus, Denmark
Mikkel Steen Petersen
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Kristoffer Sølvsten Burgdorf
Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Erik Sørensen
Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Bitten Aagaard
Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
Barbara Forman-Ankjær
Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark
Mie Topholm Bruun
Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
Karina Banasik
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Thomas Folkmann Hansen
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Glostrup, Denmark
Mette Nyegaard
Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark
Palle Duun Rohde
Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark
Søren Brunak
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Henrik Hjalgrim
Danish Cancer Society Research Center, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Epidemiology Research, Statens Serum Institut; Department of Haematology, Copenhagen University Hospital, Rigshospitalet
Sisse Rye Ostrowski
Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Ole Birger Pedersen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
Henrik Ullum
Statens Serum Institut, Denmark
Lise Tornvig Erikstrup
Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark
Christian Erikstrup
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Summary: Background: The CC chemokine receptor 5 (CCR5) is a suggested receptor for Staphylococcus aureus leukotoxin ED. Homozygosity for the Δ32 deletion (CCR5Δ32) protects against human immunodeficiency virus infection and possibly also against leukotoxin ED. We examined the impact of CCR5Δ32 on the susceptibility to S. aureus infection, all-cause infections, and S. aureus nasal carriage, respectively, and on the concentrations of circulating chemokines in blood donors. Methods: We included 95,406 participants from the Danish Blood Donor Study (DBDS) genotyped for >650,000 single nucleotide polymorphisms. The CCR5Δ32 (rs333, MAF: 0.12) was imputed from a reference panel and validated. Infectious outcomes were identified by diagnosis codes and redeemed prescription of antibiotics in national health registers. Data on S. aureus nasal carriage and forty-seven inflammatory biomarkers were available for 6721 and 7811 participants, respectively. Cox, logistic, and linear regression models adjusted for relevant confounders were used to explore said associations. Findings: During more than 700,000 person-years of observation, we found that CCR5Δ32 was associated with neither an increased risk of redeemed dicloxacillin, hospital-treated S. aureus-associated infection (replicated in 345,996 Icelanders), redeemed antibiotics, all-cause infection, and nor with S. aureus nasal carriage. We discovered an association between CCR5Δ32 and elevated CCL4 concentrations, which were 1.26-fold higher in Δ32-heterozygotes (95%-CI: 1.23–1.30) and 2.64-fold higher in Δ32-homozygotes (95%-CI: 2.41–2.90) compared with wildtype homozygotes. Conversely, concentrations of CCL2, CXCL-10, and CCL11 were slightly lower among Δ32-heterozygotes. Interpretation: Results from this CCR5Δ32 high-prevalent cohort do not support the idea that CCR5Δ32 affects the risk of S. aureus carriage or infection to any relevant degree, in this northern European context. CCL4 was the main chemokine affected by CCR5Δ32 and was observed in higher concentration among Δ32-carriers. This study cannot rule out that S. aureus is a previous driver of CCR5Δ32 selection. Funding: The Health Research Fund of Central Denmark Region, Aarhus University, Danish Administrative Regions, Bio- and Genome Bank Denmark, Danish Blood Donor Research Foundation, Aase & Ejnar Danielsens Foundation, Højmosegård Grant, National Institute of Allergy and Infectious Diseases, and A.P. Møller Foundation for the Advancement of Medical Science.